Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 3,000 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the sale, the chief financial officer owned 137,031 shares in the company, valued at $5,481,240. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Adam Laponis also recently made the following trade(s):

• On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The stock was sold at an average price of $35.26, for a total value of $96,541.88.
• On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total value of $173,454.48.

Twist Bioscience Stock Up 3.1%

Shares of TWST opened at $41.27 on Friday. The firm has a market cap of $2.53 billion, a P/E ratio of -31.50 and a beta of 2.19. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $55.33. The stock’s 50 day moving average is $32.20 and its two-hundred day moving average is $31.27. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The business had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. Analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 5.1% in the 3rd quarter. ARK Investment Management LLC now owns 6,726,808 shares of the company’s stock valued at $189,292,000 after buying an additional 326,367 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after purchasing an additional 1,349,867 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of Twist Bioscience by 6.0% during the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after purchasing an additional 235,679 shares during the period. EdgePoint Investment Group Inc. increased its position in shares of Twist Bioscience by 71.1% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after buying an additional 1,080,722 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TWST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Stephens assumed coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Evercore ISI restated an “outperform” rating and issued a $42.00 price objective on shares of Twist Bioscience in a report on Monday, January 5th. Finally, TD Cowen lifted their target price on shares of Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.